$370.48−0.49%Close 13 Nov 2026 · Market value $30.04B
About Labcorp
Labcorp Holdings Inc. provides laboratory services that supply information to doctors, hospitals, pharmaceutical companies, researchers, and patients. It operates two segments: Dx, which offers routine and specialty clinical testing through primary and specialty laboratories in the U.S. and Canada, and BLS, which provides drug development services including central laboratory, safety assessment, and clinical trial sample management to pharmaceutical and biotechnology companies. Dx also serves physicians, health systems, health plans, and consumers, with patient service centers across the U.S. The company reports that its operations span approximately 100 countries, with employees located in 17 countries.
A summary of the business section of the company's latest annual report, filed 24 Feb 2026.
Company facts
| Ticker | LH · NYSE |
|---|
| Sector | Healthcare |
|---|
| Industry | Health Care Services |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 920148 |
|---|
| Latest annual report | 10-K, filed 24 Feb 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| ADAM H. SCHECHTER | President & CEO · Director | 397K · < 1% | Sale under a 10b5-1 plan, 11 Aug 2026 |
|---|
| BRIAN J. CAVENEY | EVP, Pres of ED, CMO & CSO | 74.1K · < 1% | Grant or award, 26 Mar 2026 |
|---|
| MARK S. SCHROEDER | EVP, Pres Diagnostics & COO | 57.0K · < 1% | Shares withheld for tax, 26 Mar 2026 |
|---|
| PETER M. NEUPERT | Director | 13.8K · < 1% | Option exercise, 11 Feb 2026 |
|---|
| GARHENG KONG | Director | 13.7K · < 1% | Option exercise, 11 Feb 2026 |
|---|
| KERRII B. ANDERSON | Director | 9.9K · < 1% | Sale under a 10b5-1 plan, 17 Aug 2026 |
|---|
| JULIA A. WANG | Chief Financial Officer, EVP | 9.8K · < 1% | Option exercise, 11 Feb 2026 |
|---|
| MEGAN D. BAILEY | EVP, Pres, Central Labs & Intl | 7.9K · < 1% | Shares withheld for tax, 26 Mar 2026 |
|---|
| JEFFREY A. DAVIS | Director | 5.5K · < 1% | Option exercise, 11 Feb 2026 |
|---|
| KATHRYN E. WENGEL | Director | 4.1K · < 1% | Option exercise, 11 Feb 2026 |
|---|
| RICHELLE P. PARHAM | Director | 3.4K · < 1% | Option exercise, 11 Feb 2026 |
|---|
| KIRSTEN M. KLIPHOUSE | Director | 3.2K · < 1% | Option exercise, 11 Feb 2026 |
|---|
| PAUL B. ROTHMAN | Director | 2.6K · < 1% | Option exercise, 11 Feb 2026 |
|---|
| Summy Amy B. | EVP, Chief Marketing Officer | — | Open-market sale, 4 Aug 2026 |
|---|
| Wilkinson Peter J | SVP, Chief Accounting Officer | — | Open-market sale, 3 Aug 2026 |
|---|
| Kyle Kathryn W | EVP, Chief Legal Officer | — | Sale under a 10b5-1 plan, 2 Jul 2026 |
|---|
| Vaughn Bryan T | EVP and President, Diagnostics | — | Sale under a 10b5-1 plan, 2 Jul 2026 |
|---|
| Meltzer Jonathan C | EVP, Operations | — | Sale under a 10b5-1 plan, 27 Mar 2026 |
|---|
| GRAHAM ANITA Z | EVP, CHRO | — | Grant or award, 26 Mar 2026 |
|---|
| van der Vaart Sandra D | EVP, Corporate Affairs | — | Grant or award, 26 Mar 2026 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
LH in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.